FRANKFURT (Reuters) - Bayer's eye medication Eylea does not offer an advantage over a rival product from Novartis when treating patients with a type of diabetes-related swelling of the retina, a German healthcare cost watchdog said on Monday.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment